Stock Events

Stock Events

Search...

CanSino Biologics

€2.06

4

-€0.04-1.9% Friday 07:59

Statistics

Day High

2.06

Day Low

2.06

52W High

-

52W Low

-

Volume

0

Avg. Volume

-

Mkt Cap

848.21M

P/E Ratio

-

Dividend Yield

-

Dividend

-

Upcoming

Dividends

0%Dividend Yield

10Y Growth

N/A

5Y Growth

N/A

3Y Growth

N/A

1Y Growth

N/A

Earnings

25OctExpected

Q1 2024

Q2 2024

Next

-0.09

-0.07

-0.06

-0.04

Expected EPS

-0.0472194267380132

Actual EPS

N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CJH.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

BioNTech competes directly in the development of mRNA vaccines, similar to CanSino's viral vector COVID-19 vaccine.

Moderna is a leader in mRNA technology for vaccines, directly competing with CanSino's vaccine development approach.

AstraZeneca developed a viral vector COVID-19 vaccine, similar to CanSino, making them direct competitors in the vaccine market.

Johnson & Johnson

Johnson & Johnson also developed a viral vector COVID-19 vaccine, competing in the same space as CanSino.

Pfizer, in collaboration with BioNTech, competes in the vaccine market, particularly with mRNA technology which is a leading approach in vaccine innovation.

Sinovac Biotech

Sinovac Biotech is another major Chinese biopharmaceutical company that develops vaccines, competing in the same regional market as CanSino.

Novavax develops vaccines based on protein subunit technology, offering alternative vaccine options and competing in the global vaccine market.

GlaxoSmithKline is a large pharmaceutical company with a broad vaccine portfolio, competing globally with companies like CanSino.

Sanofi is involved in vaccine development and production, competing in the same market as CanSino with a diverse range of vaccine technologies.

CureVac competes in the mRNA vaccine space, offering technologies that could rival CanSino's viral vector vaccine approach.

About

CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. In addition, it develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. Further, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CS-2023 to treat meningitis; CS-2028 for treating multivalent conjugate vaccine; CS-2032 for hingles; CS-2036 to treat polio; CS-2047 for treating tetanus; and CS-2201 DTcP for combination vaccine. CanSino Biologics Inc. was incorporated in 2009 and is headquartered in Tianjin, the People's Republic of China.

Show more...

CEO

Dr. Xuefeng Yu Ph.D.

Employees

1494

Country

CN

ISIN

CNE100003F01

WKN

000A2PGFW

Listings